Observational studyRMD open2025
Cardiovascular events in patients with myositis: results from a French retrospective cohort.
Observational study in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cluster analysis and risk prediction model construction for antisynthase syndrome-associated interstitial lung disease based on clinical, imaging, and antibody characteristics.Frontiers in medicine · 2026Article
- Myocardial involvement in inflammatory myopathies: from subclinical disease to life-threatening myocarditis.Expert review of clinical immunology · 2026Review
- Fatal cardiac complications in two patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: A dual case report.The Journal of international medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIdiopathic inflammatory myositis (IIM) are systemic diseases, including dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotising myopathy (IMNM), antisynthetase syndrome (ASSD) and overlap myositis (OM). Patients with IIM have an increased risk of premature death, largely due to cardiovascular events (CVE). The aim of this study was to describe specific and non-specific cardiac involvement in patients with IIM, and to assess the occurrence of CVE.
methodsWe conducted a retrospective observational cohort study of patients with IIM from Saint Antoine University Hospital, Paris, between 1997 and 2020. Cardiac involvement was defined as abnormalities at baseline on ECG, Holter ECG, transthoracic echocardiography, cardiac MRI or elevated cardiac biomarkers. CVE were defined as heart failure due to ischaemia, arrhythmia or conductive block, inflammatory myocarditis or resuscitation department admission.
results78 patients were included (median age 49 years; 67% female); 33 (42%) had DM, 18 (23%) ASSD, 12 (15%) OM, 11 (14%) IMNM and 4 (5%) IBM. Cardiac involvement at diagnosis was present in 12 (15%) patients; 15 (19%) had a CVE during follow-up. Patients with versus without cardiac involvement at diagnosis were more likely to present a CVE (6 (50%) vs 9 (14%); p=0.01). Median (IQR) time to CVE was shorter in patients with cardiac involvement (9 (0-34) vs 84 (26-156) months; p<0.01).
conclusionPatients with cardiac involvement at myositis diagnosis are at increased risk of CVE and experience them earlier than patients without and should be carefully followed up, particularly during the first months after diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.